Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
Ulagamadesan VenkatesanShun-Fu LeeGuillaume ParéM Angelyn BethelHelen Martina ColhounAnastasia HooverMark LakshmananYanzhu LinValentino PirroHui-Rong QianGiacomo RuotoloLars RydenJonathan M WilsonKevin L DuffinPublished in: Diabetes care (2023)
Dulaglutide was associated with a reduced 2-year rise from baseline of NT-proBNP and GDF-15. Higher rises of these biomarkers were also associated with MACE.